Skip to main content

Table 1 Summary of cohort characteristics in N = 1042 PSP cases, 171 CBD cases, and N = 910 controls

From: Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures

Variable PSP cases (N = 1042) CBD cases (N = 171) Controls (N = 910)
Age (years) 75 (45, 98) 70 (46, 96) 79 (41, 102)
Sex    
 Male 564 (54.1%) 89 (52.0%) 388 (42.6%)
 Female 478 (45.9%) 82 (48.0%) 522 (57.4%)
Age of onset (years) 68 (41, 90)
Disease duration (years) 7 (1, 32)
PSP clinical subtype    
 Richardson 568 (74.4%)
 Non-Richardson 195 (25.6%)
Braak stage    
 0 113 (14.8%) 20 (13.3%)
 I 127 (16.6%) 32 (21.3%)
 II 223 (29.2%) 50 (33.3%)
 III 234 (30.6%) 39 (26.0%)
 IV 50 (6.5%) 7 (4.7%)
 V 11 (1.4%) 1 (0.7%)
 VI 6 (0.8%) 1 (0.7%)
Thal phase    
 0 336 (44.0%) 82 (54.7%)
 1 125 (16.4%) 30 (20.0%)
 2 52 (6.8%) 14 (9.3%)
 3 188 (24.6%) 19 (12.7%)
 4 43 (5.6%) 3 (2.0%)
 5 20 (2.6%) 2 (1.3%)
CB tau pathology score 1.50 (0.25, 2.36) 0.76 (0.23, 1.75)
NFT tau pathology score 2.23 (0.83, 2.89) 2.19 (0.99, 2.67)
TA/AP tau pathology score 1.00 (0.06, 2.00) 0.52 (0.24, 1.04)
NT tau pathology score 2.15 (0.35, 2.90) 2.52 (1.23, 2.95)
  1. The sample median (minimum, maximum) is given for continuous variables. CB = coiled bodies; NFT = neurofibrillary tangles; TA = tufted astrocytes; AP = astrocytic plaques; NT = neuropil threads